Sarepta Therapeutics,, Inc. Common Stock
Market cap $2.2B
$20.55
SRPT
$20.55
-1.77% today
Buy with €1M virtual cash · No real money
Sarepta Therapeutics,, Inc. Common Stock (SRPT) is a publicly traded company listed on the XNAS. As of September 15, 2026, Invest's signal rates SRPT a Hold, with the stock up 18% over the past year. You can practice trading SRPT risk-free with €1,000,000 in virtual cash.
Key stats
As of September 15, 2026
Market Cap
$2.2B
Volume
1.5M
52-wk High
$25.32
52-wk Low
$14.68
Day High
$21.06
Day Low
$20.29
Revenue (TTM)
$2.0B
EPS (TTM)
$-1.60
Performance
1M
+13.5%
6M
+23.3%
1Y
+18.2%
Invest signal · SRPT
HoldAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
SRPT overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -45.1%Revenue
$401MEPS (diluted)
$-0.05 per shareLatest SRPT news
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
GlobeNewswire Inc. · 10h ago
2 Beaten-Down Stocks That Still Aren't Worth Buying
The Motley Fool · Jul 11
My Top 3 Biotech Stocks for May 2026
The Motley Fool · May 20
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
GlobeNewswire Inc. · May 18
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
Benzinga · Mar 27
About Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Employees
835
30-Day Win Rate · SRPT
12 days
12 days
Last 24 sessions
How to practice trading SRPT
- 1
Use the SRPT buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top SRPT traders on Invest
Full leaderboardFrequently asked questions
Is SRPT a good stock to buy right now?
As of September 15, 2026, Invest's signal rates SRPT a Hold, based on its price trend, valuation, and fundamentals, with the stock up 18% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading SRPT risk-free first.
What is Sarepta Therapeutics,, Inc. Common Stock's (SRPT) market cap?
Sarepta Therapeutics,, Inc. Common Stock has a market capitalization of approximately $2.2B, on trailing-twelve-month revenue of about $2.0B.
How has SRPT stock performed?
SRPT is up 18% over the past year and up 23% over six months. Its 52-week range runs roughly from $14.68 to $25.32. Past performance doesn't predict future results.
How can I practice trading SRPT for free?
On Invest you get €1,000,000 in virtual cash and can buy SRPT at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.